androstenediol has been researched along with Adenocarcinoma, Basal Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beranek, PA; Bonney, RC; James, VH; Jones, DL; Reed, MJ; Scanlon, MJ | 1 |
| Bird, CE; Clark, AF; Masters, V; Sterns, EE | 1 |
| Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D | 1 |
| Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 1 |
4 other study(ies) available for androstenediol and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Adult; Aged; Androstenediol; Androstenediols; Breast; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; Humans; Menopause; Middle Aged; Radioimmunoassay | 1984 |
Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
Topics: Adenocarcinoma; Adult; Aminoglutethimide; Androstenediol; Androstenediols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Hydrocortisone; Kinetics; Menopause; Metabolic Clearance Rate; Middle Aged | 1982 |
Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Androstenediol; Antineoplastic Agents, Hormonal; Bone Neoplasms; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Testosterone | 1997 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |